Monoclonal antibodies and Fc fragments for treating solid tumors

Figures & data

Table 1 Food and Drug Administration approved monoclonal antibodies for therapy of solid tumors

Antibody	Trade name	Target	Indication
Cetuximab	Erbitux^®	EGFR	CRC (m), SCCHN (loc ad, rec)
Panitumumab	Vectibix^®	EGFR	CRC (m)
Trastuzumab	Herceptin^®	HER2	BC (ad, m), AC of GE junction
Bevacizumab	Avastin^®	VEGF	CRC (m), SCCHN (loc ad, rec), BC (m), RCC (ad), glioblastoma
Girentuximab	Rencarex^®	Carbonic anhydrase IX	RCC
Ipilimumab	Yervoy^®	CTLA-4	MM (met)

Abbreviations: AC, adenocarcinoma; ad, advanced; BC, breast cancer; CRC, colorectal cancer; CTLA-4, cytotoxic T lymphocyte antigen-4; EGFR, epidermal growth factor receptor; GE, gastroesophageal; HER2, human epidermal growth factor receptor-2; loc adv, locally advanced; m, metastatic; MM, malignant melanoma; RCC, renal cell carcinoma; rec, recurrent; SCCHN, squamous cell carcinoma of the head and neck; VEGF, vascular endothelial growth factor.